Fig. 4From: Exploring the therapeutic potential of isoorientin in the treatment of osteoporosis: a study using network pharmacology and experimental validationISO dose-dependently inhibits RANKL-induced osteoclast formation and differentiation. A, B RAW264.7 cell viability as assessed by CCK-8 assay following treatment with or without indicated concentrations of ISO for 48 and 96 h. C RANKL-stimulated RAW264.7 cells treated with or without the indicated concentrations of ISO were stained with TRAP, and representative images were shown. D The number of TRAP+ multinucleated OCs with three or more nuclei was quantified. E RANKL-stimulated RAW264.7 cells treated with or without the indicated concentrations of ISO and TRAP activity was assayed. The above values were presented as mean ± standard deviation (n = 3); Scale bar = 100 μm *p < 0.05, **p < 0.01Back to article page